https://scholars.lib.ntu.edu.tw/handle/123456789/590974
標題: | Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial | 作者: | Park, Keunchil Özgüroğlu, Mustafa Vansteenkiste, Johan Spigel, David CHIH-HSIN YANG Ishii, Hidenobu Garassino, Marina de Marinis, Filippo Szczesna, Aleksandra Polychronis, Andreas Uslu, Ruchan Krzakowski, Maciej Lee, Jong-Seok Calabrò, Luana Arén Frontera, Osvaldo Xiong, Huiling Bajars, Marcis Ruisi, Mary Barlesi, Fabrice |
關鍵字: | Avelumab; Non–small cell lung cancer; PD-L1; Phase 3; Second-line | 公開日期: | 2021 | 出版社: | ELSEVIER SCIENCE INC | 卷: | 16 | 期: | 8 | 起(迄)頁: | 1369 | 來源出版物: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 摘要: | In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report greater than 2-year follow-up data. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/590974 | ISSN: | 1556-0864 | DOI: | 10.1016/j.jtho.2021.03.009 | SDG/關鍵字: | avelumab; docetaxel; monoclonal antibody; platinum; programmed death 1 ligand 1; clinical trial; controlled study; follow up; human; lung; lung tumor; phase 3 clinical trial; randomized controlled trial; tumor recurrence; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Docetaxel; Follow-Up Studies; Humans; Lung; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。